
-
'Noble to attend': Budapest prepares for 'banned' Pride march
-
Art market banking on new generation of collectors
-
Turning 80, UN faces fresh storm of doubts
-
'A great start': NBA crown just the beginning for Shai
-
Man City hit six to reach Club World Cup last 16, Real Madrid win with 10 men
-
Iran vows retaliation after US strikes on nuclear sites
-
'Massive' Russian attack on Kyiv kills at least five: Ukraine
-
Groundbreaking Vera Rubin Observatory reveals first images
-
Thunder beat Pacers in game seven, cap stunning season with NBA crown
-
Pacers 'hearts dropped' after Haliburton injury: Carlisle
-
Ukraine says 'massive' Russian attack on Kyiv
-
Thunder's Gilgeous-Alexander named NBA Finals MVP
-
Thunder beat injury-hit Pacers in game seven to win NBA title
-
Oil prices spike after US strikes on Iran
-
Man City demolish Al Ain to reach Club World Cup last 16
-
Thunder beat Pacers to clinch first NBA Finals crown
-
Bone collectors: searching for WWII remains in Okinawa
-
Madrid coach Alonso says Rudiger complained of racist insult in Club World Cup win
-
Girls shouldn't shout?: Women break the mould at French metal festival
-
Indian activists seek to save child brides
-
Jonathan Anderson set for Dior debut at Paris Fashion Week
-
Ukraine says 'massive' Russian drone attack on Kyiv
-
Oasis: from clash to cash
-
Toxic threat from 'forever chemicals' sparks resistance in Georgia towns
-
All Blacks name five debutants in squad for France Tests
-
Pacers' Haliburton hurt early in game seven against Thunder
-
Suicide attack on Damascus church kills at least 22
-
French police probe fake Disneyland 'marriage' with nine-year-old
-
Ohtani bags strikeouts, home run as Dodgers rout Nats
-
Hall of Fame trainer Lukas ill, won't return to racing: Churchill Downs
-
US Ryder Cup captain Bradley edges Fleetwood to win PGA Travelers
-
Alonso says Rudiger complained of racist insult
-
Minjee Lee wins Women's PGA Championship for third major title
-
US bases in the Middle East
-
More than 20 killed in suicide attack on Damascus church
-
Ten-man Real Madrid show class in Pachuca win
-
Blood, destruction at Damascus church after suicide attack
-
Tesla launches long-discussed robotaxi service
-
Palou wins at Road America to boost IndyCar season lead
-
Bumrah says 'fate' behind Brook's exit for 99 against India
-
Gout Gout says 100m 'too short' for him
-
Democrats assail 'erratic' Trump over Iran strikes
-
Iran threatens US bases in response to strikes on nuclear sites
-
NBA Suns trade star forward Kevin Durant to Rockets
-
At least 20 killed in suicide attack on Damascus church
-
NATO strikes spending deal, but Spain exemption claim risks Trump ire
-
Queen's champion Alcaraz in the groove ahead of Wimbledon
-
Yildiz stars as Juventus beat Wydad at Club World Cup
-
Bumrah and Brook shine to leave England-India opener in the balance
-
Pogba says he is talking to a club about comeback after ban

Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - REGN
NEW YORK, NY / ACCESS Newswire / March 10, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:
https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=135012&wire=1
or contact Joseph E. Levi, Esq. via email at [email protected] or call (212) 363-7500 to speak to our team of experienced shareholder advocates.
THE LAWSUIT: A class action securities lawsuit was filed against Regeneron Pharmaceuticals, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between November 2, 2023 and October 30, 2024.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Regeneron paid credit card fees to distributors on the condition that distributors did not charge, one of the Company's primary products, Eylea customers more to use a credit card; (2) these payments subsidized the prices that customers paid when using credit cards to purchase Eylea; (3) as a result, Regeneron offered a price concession that lowered Eylea's selling price; (4) because retina practices were sensitive to higher prices when using credit cards to purchase anti-VEGF medications, Regeneron's price concessions provided a competitive advantage; (5) as a result of the foregoing, Regeneron misleadingly boosted reported Eylea sales; (6) by failing to report its payment of credit card fees as price concessions, Regeneron overstated the ASP reported to federal agencies, thereby violating the False Claims Act; and (7) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
WHAT'S NEXT? If you suffered a loss in Regeneron stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=135012&wire=1 to learn about your rights to seek a recovery. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
https://zlk.com/
SOURCE: Levi & Korsinsky, LLP
View the original press release on ACCESS Newswire
D.Qudsi--SF-PST